Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of D/C/F/TAF FDC vs Separate Agents in Healthy Subjects
NCT04236453Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emtricitabine + cobicistat + darunavir + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration and Area Under the Analyte Concentration-time Curve from time Zero to Last Quantifiable time. Started Jan 2020; status: terminated.
02
Drugs
emtricitabine + cobicistat + darunavir + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04236453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236453.